SCHEMBL6786302

SCHEMBL6786302

O=C1Nc2ccc(C(=O)N3CCOCC3)cc2OC1c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.52
POLB P06746 2/20 0.50
TSHR P16473 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HPGD P15428 5/20 0.47
BRD4 O60885 1/20 0.44
CREBBP Q92793 1/20 0.44
ALDH1A1 P00352 2/20 0.44
PKM P14618 1/20 0.43
PARP1 P09874 1/20 0.42
KMT2A Q03164 2/20 0.41
DNMT1 P26358 1/20 0.41
PTPN7 P35236 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6781486 0.75 SMN1; SMN2 (0.49) CNR1POLBTSHRSMN1; SMN2HPGD
SCHEMBL6782250 0.75 HPGD (0.51) CNR1TSHRHPGDALDH1A1PKM
SCHEMBL6415562 0.73 HPGD (0.58) CNR1POLBTSHRHPGDALDH1A1
SCHEMBL6780554 0.71 HPGD (0.52) CNR1POLBHPGDPKMKMT2A
SCHEMBL4970806 0.71 BRD4 (0.55) HPGDBRD4CREBBPALDH1A1PARP1
SCHEMBL30943193 0.71 BRD4 (0.55) POLBBRD4CREBBPPARP1
SCHEMBL2363289 0.71 BRD4 (0.61) BRD4CREBBPALDH1A1PARP1
SCHEMBL30991575 0.71 BRD4 (0.55) BRD4CREBBPPARP1
SCHEMBL30991578 0.71 BRD4 (0.55) POLBBRD4CREBBPPARP1
SCHEMBL5670399 0.70 CA2 (0.62) POLBHPGDBRD4CREBBPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299395-B1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS UPJOHN CO (US) 2004-09-15 EP disclosed
US-6673793-B2 N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY PHARMACIA & UPJOHN CO. 2004-01-06 US disclosed
EP-1299395-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2003-04-09 EP disclosed
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed
WO-2002004462-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections ZC3HAV1, RPL5, ZC3HAV1L CNR1 3686/4885POLB 418/4885TSHR 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.